Search Results - "Bartalucci, Giulia"

Mycoplasma hominis as Cause of Extragenital Infection in Patients with Hypogammaglobulinemia: Report of 2 Cases and Literature Review by Russo, Chiara, Mikulska, Malgorzata, Delfino, Emanuele, Toscanini, Federica, Mezzogori, Laura, Schiavoni, Riccardo, Bartalucci, Claudia, Angelucci, Emanuele, Bartalucci, Giulia, Gambella, Massimiliano, Raiola, Anna Maria, Morici, Paola, Crea, Francesca, Chiola, Silvia, Morbelli, Silvia Daniela, Marchese, Anna, Bassetti, Matteo

“…Mycoplasma hominis can be a part of human urogenital tract microbiome, and it is a frequent cause of urogenital infections. In rare cases, it can also cause…”
Get full text

The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case Study by Sepulcri, Chiara, Dentone, Chiara, Mikulska, Malgorzata, Bruzzone, Bianca, Lai, Alessia, Fenoglio, Daniela, Bozzano, Federica, Bergna, Annalisa, Parodi, Alessia, Altosole, Tiziana, Delfino, Emanuele, Bartalucci, Giulia, Orsi, Andrea, Di Biagio, Antonio, Zehender, Gianguglielmo, Ballerini, Filippo, Bonora, Stefano, Sette, Alessandro, De Palma, Raffaele, Silvestri, Guido, De Maria, Andrea, Bassetti, Matteo

“…Abstract Background Immunocompromised patients show prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in nasopharyngeal swabs…”
Get full text

Radiotherapy with rituximab as first-line treatment for early-stage follicular lymphoma by Cencini, Emanuele, Fabbri, Alberto, Schiattone, Luana, Bartalucci, Giulia, Bocchia, Monica

Get full text

Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma by Bartalucci, Giulia, Coviello, Elisa, Guolo, Fabio, Minetto, Paola, Gambella, Massimiliano, Rivoli, Giulia, Guardo, Daniela, Ballerini, Filippo, Miglino, Maurizio, Fabbri, Alberto, Lemoli, Roberto M, Bocchia, Monica, Gobbi, Marco

“…BACKGROUND AND AIMS Diffuse Large B Cell Lymphoma (DLBCL) is an heterogeneous group of diseases whose behavior can be predicted by clinical risk scores,…”
Get full text

Low-dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma by Cencini, Emanuele, Fabbri, Alberto, Schiattone, Luana, Bartalucci, Giulia, Bocchia, Monica

Get full text

Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia by Gozzetti, Alessandro, Candi, Veronica, Fabbri, Alberto, Schiattone, Luana, Cencini, Emanuele, Lauria, Francesco, Frasconi, Adele, Crupi, Rosaria, Raspadori, Donatella, Papini, Giulia, Defina, Marzia, Bartalucci, Giulia, Bocchia, Monica

“…Highlights • FCR is an oral regimen with reported limiting toxicity, not very used in old CLL patients. • Median age in CLL is 72, most of clinical trials…”
Get full text

Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas by Fabbri, Alberto, Cencini, Emanuele, Rigacci, Luigi, Bartalucci, Giulia, Puccini, Benedetta, Dottori, Roberto, Gozzetti, Alessandro, Bosi, Alberto, Bocchia, Monica

“…Abstract Indolent non-Hodgkin lymphomas (iNHLs) are B-cell neoplasms for which no consensus is available about optimal first-line therapy. Chemoimmunotherapy…”
Get full text

Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy by Bocchia, Monica, Aprile, Lara, Sirianni, Santina, Abruzzese, Elisabetta, Gozzini, Antonella, Castagnetti, Fausto, Puccetti, Luca, Sorà, Federica, Galimberti, Sara, Sicuranza, Anna, Tiribelli, Mario, Breccia, Massimo, Iurlo, Alessandra, Bartalucci, Giulia, Cattaneo, Daniele, Mulas, Olga, Baratè, Claudia, Caocci, Giovanni, Sica, Simona, Rosti, Gianantonio, Bosi, Alberto, Raspadori, Donatella

“…Introduction: In chronic myeloid leukemia (CML), tyrosine Kinase Inhibitors (TKIs) treatment is a potentially life-time therapy for the majority of patients…”
Get full text